Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, International, Multi-center, Open-label Study to Document Optimal Timing of Initiation of Dronedarone Treatment After Conversion With Loading Dose of Amiodarone in Patients With Persistent Atrial Fibrillation Requiring Conversion of AF

Next Previous
Trial Profile

A Randomized, International, Multi-center, Open-label Study to Document Optimal Timing of Initiation of Dronedarone Treatment After Conversion With Loading Dose of Amiodarone in Patients With Persistent Atrial Fibrillation Requiring Conversion of AF

Status: Discontinued
Phase of Trial: Phase IV

Latest Information Update: 14 Oct 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dronedarone (Primary) ; Amiodarone
  • Indications Atrial fibrillation
  • Focus Pharmacogenomic; Therapeutic Use
  • Acronyms ARTEMIS AF Loading; ARTEMIS Load
  • Sponsors Sanofi

    • Most Recent Events

    • 14 Oct 2021 This trial has been completed in France (End Date: 14 Dec 2011), according to European Clinical Trials Database record.
    • 08 Dec 2020 Greece, Hungary and Turkey were the planned location as per European Clinical Trials Database record.
    • 01 Sep 2020 Status changed to discontinued, according to results published in the Journal of Cardiovascular Pharmacology and Therapeutics
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top